The new drug in question, UBT251, is a next-generation therapy designed to tackle obesity and type 2 diabetes by targeting three key hormones including, GLP-1 and GIP — which regulate appetite and ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited ...

With the United Lab deal, it has gained the rights to develop, manufacture and sell its experimental drug, UBT251. Sign up here. UBT251 belongs to a class of drugs that target a combination of gut ...

What's more, the Danish giant has just announced a US$2-billion deal with Chinese pharmaceutical company United Biotechnology, to license it's novel weight-loss and diabetes drug UBT251 to the ...

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon. Wegovy already inhibits GLP-1 ...

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company. Novo Nordisk will pay $200 million up front, with up to $1.8 billion in ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

United Biotechnology will get $200M upfront, up to $1.8B in milestones, and royalties as part of its UBT251 licensing deal with Novo Nordisk A phase 1b trial of UBT251 showed a 15.1% weight loss ...

Novo Nordisk, which earlier Monday lost its crown as Europe’s most valuable company, said it signed an exclusive global licensing deal for UBT251, a drug that targets three different hormones to ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...